GLP-3 vs GLP-1: The Triple Agonist vs the Established Class (2026)
If you are comparing "GLP-3 vs GLP-1," here is the honest framing first: this is not one drug versus another, and "GLP-3" is not a real receptor. It is a receptor-generation story. "GLP-1" is the established class, the single GLP-1 drug semaglutide and the dual GIP/GLP-1 drug tirzepatide, both FDA-approved. "GLP-3" is the colloquial, marketing-flavored nickname for the next generation: the triple agonist retatrutide, which hits three receptors at once and is still investigational. To see how these rank against every metabolic option people use, our guide to the best peptides for weight loss is the hub above this class comparison. The cleanest way to read the whole question is as a ladder of receptor count: one receptor, then two, then three, with each added receptor buying a different fat-loss lever.
So the real decision is not "which molecule wins" but "do I want the established, approved generation I can actually be prescribed, or the experimental top of the ladder that loses the most weight in trials but is not legal to obtain as medicine?" This page is the class-level orientation. For the molecular science of how a triple agonist works, and for each molecule's full profile, we link out so this page stays a clean decision hub.
Head-to-head
Edge: GLP-1 class — by a clear margin
This is a drug-CLASS comparison across receptor generations, not a single-molecule switch: the established GLP-1 class (single GLP-1 like semaglutide, plus the dual GIP/GLP-1 tirzepatide) versus the emerging triple agonist, marketed colloquially as 'GLP-3' and embodied by retatrutide (GIP + GLP-1 + glucagon). The honest decision is that for almost everyone today the GLP-1 class wins, because it is FDA-approved, prescribable, and backed by deep trial and real-world evidence, while the triple agonist is investigational and not legally available outside a trial. The triple agonist's only edge is peak trial effectiveness (Phase 2 reta ~24.2% vs SURMOUNT-1 tirz ~22.5% vs STEP 1 sema ~14.9%), which is exactly why it is the headline. The moat is the secondary signal: among ~11,400 weight-loss-cohort users the established GLP-1 class dominates (tirzepatide 32% + semaglutide 26%, ~58%) while retatrutide is already a fast-growing 16% experimental cohort. 'GLP-3' is not an official receptor name; it is shorthand for the third receptor generation.
Overall fit score
By dimension
Side by side
| GLP-1 class | GLP-3 / triple agonist | |
|---|---|---|
| Receptor targets / agonist count | 1-2 receptors: GLP-1 alone (semaglutide) or GLP-1 + GIP (tirzepatide) | 3 receptors: GLP-1 + GIP + glucagon (retatrutide) |
| Example molecules | Semaglutide (Ozempic/Wegovy); tirzepatide (Mounjaro/Zepbound) | Retatrutide (LY3437943); the colloquial 'GLP-3' |
| FDA status (weight loss) | Approved (Wegovy 2021; Zepbound 2023) | Investigational, not approved (Phase 3 TRIUMPH) |
| Best trial weight loss | ~14.9% sema (STEP 1, 68 wk); ~22.5% tirz (SURMOUNT-1, 72 wk) | ~24.2% reta (Phase 2, 48 wk, 12 mg) |
| Mechanism added per receptor | GLP-1: appetite + slowed gastric emptying. + GIP: more appetite effect, less nausea | + glucagon: raises energy expenditure, burns fat (incl. liver fat) on the 'calories out' side |
| Route | Once-weekly subcutaneous injection (oral semaglutide also exists) | Once-weekly subcutaneous injection |
| Community share (weight-loss cohort) | ~58%: tirzepatide 32% + semaglutide 26% (~11,400 users) | 16% retatrutide (fast-growing experimental cohort) |
| Evidence base | Deep: multiple Phase 3 programs + CV outcome trials + years of real-world use | Shallow: one published Phase 2, Phase 3 ongoing; no long-term outcome data |
Educational. At least one option here is investigational (in trials, not FDA-approved). Not medical advice, not a claim either is proven better or safe for you. Community figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- "GLP-3" is not an official receptor or drug class. It is informal shorthand for the next-generation triple agonist (GIP + GLP-1 + glucagon), almost always meaning retatrutide. The body makes GLP-1 and GLP-2; it never makes a "GLP-3."
- It is a receptor-count ladder. Single GLP-1 (semaglutide) to dual GIP/GLP-1 (tirzepatide) to triple GIP/GLP-1/glucagon (retatrutide). Each rung adds a receptor and a different lever.
- Trial weight loss climbs up the ladder: about 14.9% for semaglutide (STEP 1), about 22.5% for tirzepatide (SURMOUNT-1), about 24.2% for retatrutide (Phase 2). Different trials, so directional, not a head-to-head race.
- The established GLP-1 class wins for almost everyone today because it is approved, prescribable, and deeply evidenced. The triple agonist's only clear edge is peak trial effectiveness.
- The "GLP-3" drug is not available. Retatrutide is investigational (Phase 3 TRIUMPH); the only legitimate access is a clinical trial. Vials sold online are an unapproved gray market.
- What the community uses: among about 11,400 weight-loss-cohort users, the GLP-1 class dominates (tirzepatide 32% + semaglutide 26%, about 58%), while retatrutide is already a fast-growing 16% experimental cohort.
GLP-3 vs GLP-1 at a glance
The structure is simpler than the marketing suggests: the GLP-1 class is the approved, evidenced generation; the triple agonist "GLP-3" is the experimental top of the ladder that wins on peak trial weight loss and loses on everything to do with access and evidence.
| Dimension | GLP-1 class (single & dual) | "GLP-3" / triple agonist |
|---|---|---|
| Receptors / agonist count | 1-2: GLP-1 (sema) or GLP-1 + GIP (tirz) | 3: GLP-1 + GIP + glucagon (reta) |
| Example molecules | Semaglutide, tirzepatide | Retatrutide (LY3437943) |
| FDA status (weight) | Approved (Wegovy, Zepbound) | Investigational (Phase 3 TRIUMPH) |
| Best trial weight loss | ~14.9% sema; ~22.5% tirz | ~24.2% reta (Phase 2) |
| Mechanism added per receptor | GLP-1 appetite; + GIP appetite/tolerability | + glucagon: energy expenditure, fat burn |
| Route | Weekly injection (oral sema exists) | Weekly injection |
| Evidence base | Deep (Phase 3 + CV outcomes + real-world) | Shallow (one Phase 2, Phase 3 ongoing) |
| Community share (weight-loss cohort) | ~58% (tirz 32% + sema 26%) | 16% (retatrutide) |
What is "GLP-3," really?
"GLP-3" is not an official receptor or hormone; it is consumer-and-marketing shorthand for the next generation of weight-loss drug, the triple agonist retatrutide, which activates three receptors at once instead of one. The "GLP" is borrowed from GLP-1, and the "3" stands colloquially for "third generation" or "three receptors."
Here is the honest mechanism. Your body cleaves a precursor protein called proglucagon into the real peptides GLP-1 and GLP-2, both genuine gut hormones. There is no natural "GLP-3." When the first blockbuster weight-loss drug was a GLP-1, that name became the household label for the whole category; when a stronger drug arrived, the intuitive shorthand was to bump the number. GLP-2 was already a real hormone, so "GLP-3" became the informal label for "the strongest one." The number is doing the work of "next generation," not naming a fourth hormone.
That matters because some vendors lean on the "GLP-3" name to make a research-chemical vial sound like an officially recognized new class. It is not one. We keep the deep molecular science on the dedicated hub rather than repeating it here: see the full explainer at GLP-3 and triple agonists explained.
Citation capsule. There is no receptor or drug class officially named "GLP-3." Human proglucagon is cleaved into GLP-1 and GLP-2; GLP-2 is an intestinotrophic gut hormone, not an appetite drug. "GLP-3" is informal shorthand for the next-generation triple agonist (GIP + GLP-1 + glucagon), most commonly the investigational drug retatrutide. Sources: Wikipedia, "Proglucagon," 2026; Eli Lilly investor release, 2025.
The agonist-count ladder: one receptor to three
The whole "GLP-3 vs GLP-1" question is best read as a ladder of how many receptors a single molecule activates, because each added receptor buys a distinct fat-loss lever. Single hits GLP-1, dual adds GIP, triple adds glucagon. The drugs got more ambitious as researchers learned that combining receptor targets in one molecule produced more weight loss than a GLP-1 alone.
In plain terms, weight regulation is a control panel with several switches. The first generation flipped one switch, appetite, through GLP-1. The dual agonist added a second, GIP, which boosts the appetite effect and tends to reduce GLP-1's nausea. The triple agonist adds a third, glucagon, and this one is different in kind: instead of leaning further on eating less, it nudges the body to burn more energy and oxidize fat, including liver fat. That extra "calories out" lever is the single most important thing the third receptor buys, and it is why a triple agonist is not simply "a stronger Ozempic."
The figure below is the signature view of this page: the ladder of receptor count, each rung labeled with its added lever and its example molecule. We keep the receptor-by-receptor pharmacology shallow here on purpose and point to the hub for depth: GLP-3 and triple agonists explained.
Is "GLP-3" better than GLP-1 for weight loss?
On peak trial weight loss alone, yes, the triple agonist edges the GLP-1 class, but that single advantage is the only place it wins, and it is offset by the fact that it is not approved or available. Average weight loss has climbed up the ladder, from the mid-teens with a single GLP-1, to the low twenties with a dual agonist, to about 24% with the triple agonist.
The numbers, from each drug's landmark trial: semaglutide lost about 14.9% of body weight at 68 weeks in STEP 1 (NEJM, 2021); tirzepatide lost about 22.5% at its highest dose in SURMOUNT-1 (Jastreboff et al., NEJM, 2022); and retatrutide lost about 24.2% at the 12 mg dose at 48 weeks in its Phase 2 obesity trial (Jastreboff et al., NEJM, 2023). One honest caveat before reading too much into the climb: these are separate trials with different lengths, doses, and patient mixes, so the ladder is directional, not a head-to-head race. No trial has pitted all three against each other.
There is a quieter point buried in those numbers that changes the practical answer. The biggest jump on the ladder is from single to dual, roughly 15% to 22.5%, and the dual agonist tirzepatide is already FDA-approved. The gap from dual to triple, about 22.5% to 24%, is real but modest by comparison. So if "I want the most weight loss I can actually get" is the goal, the honest recommendation is usually the dual agonist within the approved GLP-1 class, not the experimental triple agonist for a couple of extra percentage points you cannot legally obtain.
What each added receptor buys: GIP and glucagon
The reason the ladder works is that GIP and glucagon are not just "more GLP-1"; each adds a mechanically different effect, and glucagon in particular opens a lever GLP-1 drugs do not have. Understanding what each receptor does is the difference between "GLP-3 is just stronger" and knowing why.
GIP, the second receptor, is thought to enhance the appetite and metabolic effect of GLP-1 while reducing the nausea that GLP-1 drugs can cause. That combination, more effect with often better tolerability, is a big part of why the dual agonist tirzepatide out-lost pure semaglutide in trials. Glucagon, the third receptor, is the defining lever of the triple agonist. Counterintuitively for a hormone known to raise blood sugar, glucagon receptor agonism, when balanced with GLP-1 and GIP, raises energy expenditure and enhances fat oxidation, including reducing fat in the liver. In plain language, the first two receptors mostly work on the "calories in" side by making you eat less; glucagon adds a "calories out" lever.
That extra lever is also the extra risk. A third mechanism is a third way for a drug to cause unintended effects, and glucagon's influence on blood sugar and the heart is exactly why a triple agonist needs full Phase 3 testing before anyone can call it safe. More mechanism is more power and more unknowns at once. We keep the receptor-level pharmacology on the hub and the molecule pages: see GLP-3 and triple agonists explained and the retatrutide guide.
This is also the cleanest way to answer the related search, "is the triple agonist just a stronger Ozempic?" The honest answer is no, not quite, because the kind of effect is different, not only the size. A pure GLP-1 and, to a large extent, a dual agonist mostly move the "calories in" side of the equation: you feel full sooner, eat less, and lose weight as a downstream result. The glucagon receptor is the first lever in this family that reaches the "calories out" side, nudging the body to spend more energy and to actively mobilize and oxidize stored fat. That is why the triple agonist drew interest well beyond the scale number, particularly for fatty-liver disease, where reducing fat inside the liver matters as much as overall weight. So the ladder is not just "more of the same, turned up"; the top rung adds a genuinely new mode of action, which is both the reason it lost the most weight in trials and the reason it carries the least-understood risk profile.
How the ProtocolPlus community splits across the generations
Because there is no single "GLP-3 vs GLP-1" head-to-head in real use, the most useful signal is which generation the weight-loss community actually reaches for, and there the established GLP-1 class dominates while the triple agonist is a fast-growing experimental minority. This is usage data, what people track, not a clinical efficacy ranking or an endorsement of using an investigational drug.
In our app data, among about 11,400 users in the weight-loss cohort, the established GLP-1 class is the clear majority: tirzepatide at 32% (3,648 users) and semaglutide at 26% (2,964 users) together account for roughly 58% of the cohort. The triple agonist retatrutide is already at 16% (1,824 users), a striking share for a drug that is not even approved, and it reads as a fast-growing experimental cohort rather than a mainstream choice. The signature view below maps the generation share onto the same receptor-count ladder, so you can see adoption and agonist count side by side.
Access and legality: the part that actually decides it
For almost everyone, the deciding factor is not the weight-loss percentage but availability: the GLP-1 class is FDA-approved and prescribable, while the triple agonist "GLP-3" is investigational, so there is no legal way to be prescribed it as a medicine. Strength and availability run in opposite directions on this ladder.
Semaglutide and tirzepatide are approved (Wegovy in 2021, Zepbound in 2023) and have years of real-world use and cardiovascular outcome data behind them. Retatrutide is being developed by Eli Lilly and is running through the Phase 3 TRIUMPH program; until those trials finish and a regulator reviews them, it remains experimental (Eli Lilly, 2025). That has two practical consequences. First, the only legitimate way to receive retatrutide is by enrolling in a clinical trial. Second, vials sold online as "retatrutide" or "GLP-3" labeled "for research use only" are unapproved research chemicals: not quality-verified, not legal to use as medicine, and not something a clinician can responsibly prescribe.
This is why the community split above matters more than the trial ladder for a real decision. The 16% of the cohort tracking retatrutide are, by definition, using a research-grade compound outside the approved system. That is a meaningfully different risk posture from a prescribed, pharmacy-dispensed GLP-1 drug, and it is the honest reason the established class scores far higher on accessibility and safety even though it loses the trial-effectiveness line.
It is worth naming the trap directly, because it is the single biggest mistake in the "GLP-3 vs GLP-1" search. People assume the strongest drug must also be the one you reach for, when on this ladder strength and availability run in opposite directions: the most powerful option is precisely the one you cannot legally get. That inversion is not a temporary supply problem; it is a regulatory reality. Approval exists to confirm that a drug's benefits outweigh its risks across large, long, controlled trials, and the triple agonist has not yet cleared that bar. The strong Phase 2 number is a reason to be interested, not a substitute for the safety and outcome evidence that approval represents. For a prescribed GLP-1 or dual agonist, that evidence already exists; for the triple agonist, it is still being gathered. Framed that way, "which is better" stops being a weight-loss-percentage question and becomes a question of how much unproven risk you are willing to take on for a few extra points you would have to source on a gray market.
The editorial scorecard (context, not a verdict)
Weighted across six dimensions, the established GLP-1 class scores 77 and the triple agonist "GLP-3" scores 57, and the radar shows exactly why: the triple agonist wins only effectiveness, while the GLP-1 class wins evidence, safety, accessibility, and cost. This is editorial context for the trade-off, not a clinical ruling on what is right for you.
The radar makes the shape of the decision visible. The triple agonist's outline pushes out furthest on effectiveness and matches on speed, but collapses on accessibility (it is not legally available) and evidence (one Phase 2). The GLP-1 class is the more balanced, larger overall shape precisely because it is approved and deeply studied. Read it as: the experimental top of the ladder buys you peak effectiveness and nothing else, while the established class buys you everything except the last couple of percentage points of weight loss.
Choose the GLP-1 class if... / Choose the triple agonist ("GLP-3") if...
Choose the established GLP-1 class if:
- You want a treatment you can be prescribed legally and fill at a pharmacy today.
- You value a deep evidence base: Phase 3 data, real-world use, and cardiovascular outcome trials.
- You want the most predictable safety and tolerability, ideally starting with the dual agonist tirzepatide for near-triple-tier weight loss inside the approved class.
- You are not comfortable using an investigational, research-grade compound with no regulatory oversight.
Choose the triple agonist ("GLP-3") if:
- You are specifically chasing the highest peak trial weight loss and the glucagon-driven energy-expenditure mechanism.
- You have plateaued on an approved GLP-1 or dual agonist and are exploring the next generation, under medical supervision.
- You can access it the only legitimate way, by enrolling in a clinical trial, and you accept that everything else is an unapproved gray market.
- You accept a shallower evidence base, no long-term outcome data, and a third, less-studied receptor lever.
The honest verdict
There is no clean "GLP-3 vs GLP-1" winner because they are not equals on the same shelf; they are two rungs of one ladder, separated mostly by time. For almost everyone today, the established GLP-1 class is the answer: it is approved, prescribable, deeply evidenced, and, in the dual agonist tirzepatide, already delivers most of the weight loss the triple agonist shows in trials. The triple agonist "GLP-3," retatrutide, is the more powerful drug on paper and the genuine top of the ladder, but it is investigational, unavailable outside a trial, and backed by far less evidence, which is exactly why it is a headline rather than a prescription.
The most useful way to read the comparison is the gap between strength and availability: the strongest option is the one you cannot get. If you want maximum approved weight loss, that points to the dual agonist within the GLP-1 class, not the experimental triple. For the science of how these drugs work, see GLP-3 and triple agonists explained, the retatrutide guide, and the semaglutide guide. For the molecule-versus-molecule head-to-heads, see semaglutide vs retatrutide and tirzepatide vs retatrutide. To see where each ranks against every option, see best peptides for weight loss. And for any of it, talk to a qualified clinician first.
Frequently Asked Questions
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. Retrieved 2026-06-19. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. Retrieved 2026-06-19. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial." New England Journal of Medicine, 2023. Retrieved 2026-06-19. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (investor release; TRIUMPH program; LY3437943; investigational). 2025. Retrieved 2026-06-19. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- ClinicalTrials.gov. "A Study of Retatrutide (LY3437943) in Participants With Obesity" (TRIUMPH; NCT05931367). Retrieved 2026-06-19. https://clinicaltrials.gov/study/NCT05931367
- "Triple Agonism Based Therapies for Obesity" (mechanisms of GIP and glucagon receptor agonism). PMC review, 2025. Retrieved 2026-06-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/
- Wikipedia. "Proglucagon." Retrieved 2026-06-19. https://en.wikipedia.org/wiki/Proglucagon
- ProtocolPlus. "Community usage data: weight-loss cohort" (goals/weight-loss.json). First-party app data, 2026. ~11,400 weight-loss-cohort users: tirzepatide 32%, semaglutide 26%, retatrutide 16%. Usage signal, not a clinical efficacy ranking.